Predictive Factors for Successful Vaccination Against Hepatitis B Surface Antigen in Patients Who Have Undergone Orthotopic Liver Transplantation.
Ailee Ikeda(Okayama University), Hiroyuki Okada(Harvard University), Nozomu Wada(Okayama University), Ryuichi Yoshida(Okayama University), Hidenori Shiraha(Kawasaki Medical School), Tetsuya Yasunaka(Okayama University), Hideki Onishi(Okayama University), Daisuke Nobuoka(Fukuyama City Hospital), Atsushi Oyama(Okayama University), Akinobu Takaki(Okayama University), Toshiyoshi Fujiwara(Okayama University), Fusao Ikeda(Okayama University), Kazuhiro Yoshida(Nagasaki University), Takashi Kuise(Okayama Red Cross General Hospital), Takahito Yagi(Okayama University), Takuya Adachi(Okayama University), Yuzo Umeda(Okayama University)
Cited by 3
Related Papers
Phase I Trial of a Glypican-3–Derived Peptide Vaccine for Advanced Hepatocellular Carcinoma: Immunologic Evidence and Potential for Improving Overall Survival
|Clinical Cancer Research|2012|304
CSF1/CSF1R Signaling Inhibitor Pexidartinib (PLX3397) Reprograms Tumor-Associated Macrophages and Stimulates T-cell Infiltration in the Sarcoma Microenvironment
|Molecular Cancer Therapeutics|2021|258
A nationwide survey on non-B, non-C hepatocellular carcinoma in Japan: 2011–2015 update
|Journal of Gastroenterology|2018|242